All In Biotech

Drug Trial Radar · NCT04549168

A Study of Lemborexant in Chinese Participants With Insomnia Disorder

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of the Efficacy and Safety of Lemborexant in Chinese Subjects With Insomnia Disorder

Last checked: Nov 20, 2026Latest source record: Dec 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 194 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

194

Actual

Start

Nov 6, 2020

Primary completion

Mar 17, 2023

Study completion Mar 17, 2023

Sponsor

Lead sponsor
Eisai Co., Ltd.Eisai
Sponsor type
Industry
First posted
Sep 16, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to confirm using polysomnography (PSG) that lemborexant 10 milligram (mg) is superior to placebo on objective sleep onset as assessed by latency to persistent sleep (LPS) during the last 2 nights of 1 month of treatment in participants with insomnia disorder.

Conditions

  • Sleep Initiation and Maintenance Disorders

Interventions

  • LemborexantDrug

    Lemborexant 10 mg tablet.

  • PlaceboDrug

    Placebo tablet matched to lemborexant 10 mg tablet.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline of Mean Latency to Persistent Sleep (LPS) Over the Last 2 Nights of 1 Month of Treatment of Lemborexant 10 mg Compared to PlaceboTime frame: Baseline, Days 29 and 30

Locations

23 sites in 2 countries. Site status is shown where the registry gives one.

  • Beijing Tiantan Hosptial, Capital Medical University

    Beijing, Beijing Municipality, China

  • Peking University Sixth Hospital

    Beijing, Beijing Municipality, China

  • Xuanwu Hospital Capital Medical University

    Beijing, Beijing Municipality, China

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China

  • Nanfang Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital of Jinan University

    Guangzhou, Guangdong, China

  • The First Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • The Third Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • Henan Mental Health Center

    Xinxiang, Henan, China

  • Wuhan Mental Health Center

    Wuhan, Hubei, China

  • Nanjing Brain Hosptial

    Nanjing, Jiangsu, China

  • The Second Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • Jilin First University Affiliated Hospital

    Changchun, Jilin, China

  • Inner Mongolia Autonomous Region Peoples Hospital

    Hohhot, Mongolia, China

  • Tangdu Hospital

    Xi'an, Shaanxi, China

  • Shandong Provincial Qianfushan Hospital

    Jinan, Shandong, China

  • Huashan Hospital Fudan University

    Shanghai, Shanghai Municipality, China

  • Shanghai Mental Health Center

    Shanghai, Shanghai Municipality, China

  • First Hospital of Shanxi Medical University

    Taiyuan, Shannxi, China

  • Tianjin Anding Hospital

    Tianjin, Tianjin Municipality, China

  • Taipei Veterans General Hospital

    Taipei, Taiwan

  • Chang Gung Medical Foundation Linkou Chang Gung Memorial Hospital

    Taoyuan, Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.